Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
about
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesGood clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer CellsEpidermal growth factor receptor inhibition and non-small cell lung cancer.Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersEpidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer.Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells.Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis.Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor.Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
P2860
Q24653036-B10814B0-9E9D-4426-B143-797CAC561C38Q27851566-9DD6CC0E-BE57-4D9C-9F25-17793A8EFF9FQ33693948-9B068534-DC35-4D6B-AF33-FF0BCDF238BAQ34011217-6D34C537-7C8D-418F-A1A6-89B1DE87BA85Q35078128-5D5953E6-1943-4178-BD45-8603C0801B0BQ35584647-CADD6353-4150-4BC0-8517-2F90B37E5E6BQ36065121-C0EE5BF8-5E5D-457E-9DEF-44D2433AF07FQ36504349-AFB0A6A2-9974-4F80-862E-AED876355D65Q36839768-D8224426-D41E-49C9-9CFF-4E97CF6260F1Q36905639-F44C086A-F9D1-40F9-A011-66E2077470D0Q37581685-D0224874-297E-414C-BFDC-FE39724CD484Q37637905-B918B279-73AD-4000-BC0E-BAACC70BDB9FQ37755154-28E0D19D-D4FD-402B-9B60-28F5B8BDCE9CQ37916396-51CE20B8-BD1C-46B7-8380-A7605675AD5FQ38061599-A04D7D11-1FCC-4768-A7D8-8502C779EC2AQ38697702-1E4EBFB3-6FEA-4C2D-9029-969F910116CAQ40041019-FBCD3446-2C59-46A4-8CD6-894F23548DCCQ46351405-11B58E65-0FB3-43DF-83E2-F3E95D00604AQ47159366-018B4B8C-C1D6-4A78-B534-F171392E0324Q48100116-A25FCC3B-DC40-4339-A3C5-78BC628B3F43Q50053792-E56D74C2-0DAB-4651-99BD-767A87DEE0D9Q51743342-045BCF3C-8D8D-4BAD-B444-6D6CADC011E9
P2860
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@ast
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@en
type
label
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@ast
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@en
prefLabel
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@ast
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@en
P2093
P1433
P1476
Mutations in the tyrosine kina ...... in non-small-cell lung cancer.
@en
P2093
Beatriz Cirauqui
Benjamin Besse
Carme Sarries
Cristina Queralt
Jose Javier Sanchez
Jose Luis Mate
Jose Miguel Sanchez
Ken-Ichi Nishiyama
Maria Perez
Miquel Taron
P356
10.1016/J.LUNGCAN.2005.05.017
P577
2005-10-01T00:00:00Z